

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
60623-ASerial No.  
09/788,131INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)Applicants  
Adrian Gilbert et al.Filing Date  
February 16, 2001Group Art Unit  
16142002-0-0-100  
JUL 08 2002  
C-68

## U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	US 3 8 4 7 9 1 2 5 M 5 0	11/19/74	Teitelbaum et al.			
	US 4 3 3 9 4 3 1	7/13/82	Gaffar			
	US 5 2 0 4 0 9 9	4/20/93	Barbier et al.			
	US 5 5 9 1 6 2 9	1/7/97	Rodriguez et al.			
	US 5 6 2 7 2 0 6	5/6/97	Hupe et al.			
	US 5 6 6 8 1 1 7	9/16/97	Shapiro et al.			

## FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	WO 8 8 1 0 1 2 0	12/29/88	US				
	WO 9 5 3 1 9 9 0	11/30/95	US				
	WO 9 5 3 3 4 7 5	12/14/95	Europe				
	WO 9 8 3 0 2 2 7	7/16/98	US				
	WO 0 0 0 5 2 5 0	2/3/00	US				
	WO 0 0 1 8 7 9 4	4/6/00	US				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Teitelbaum, et al., "Suppression of Experimental Allergic Encephalomyelitis by a Synthetic Polypeptide", <u>Eur. J. Immunol.</u> , 1971, 1, 242-248
	Teitelbaum, et al., "Suppression of Experimental Allergic Encephalomyelitis by a Synthetic Polypeptide", <u>Israel J. Med. Sci.</u> , 1971, 7, 630-631 (Abstract)
	Arnon, et al., "Suppression of Experimental Allergic Encephalomyelitis by a Synthetic Copolymer Immunological Cross Reactive with Basic Encephalitogen", <u>Israel J. Med. Sci.</u> , 1972, 8, 1759-1760
	Teitelbaum, et al., "Protection Against Experimental Allergic Encephalomyelitis", <u>Nature</u> , 1972, 240, 564-566
	Webb, et al., "Further Studies on the Suppression of Experimental Allergic Encephalomyelitis by Synthetic Copolymer", <u>Israel J. Med. Sci.</u> , 1972, 8, 656-657
	Teitelbaum, et al., "Suppression of Experimental Allergic Encephalomyelitis with Basic Polymers", <u>Eur. J. Immunol.</u> , 1973, 3, 273-279

EXAMINER

DATE CONSIDERED

**\*EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 60623-A	Serial N . 09/788,131			
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Applicants Adrian Gilbert et al.				
				Filing Date February 16, 2001	Group Art Unit 1614			
JUL 08 2002 PATENT DOCUMENTS		U.S. PATENT DOCUMENTS						
		Examiner Initial	Document Number			Date	Name	Class
	US 5 7 1 9 2 9 6			2/17/98	Acton III, et al.			
	US 5 8 0 0 8 0 8			9/1/98	Konfino et al.			
	US 5 8 5 8 9 6 4			1/12/99	Aharoni et al.			
	US 5 9 8 1 5 8 9			11/9/99	Konfino et al.			
	US 5 9 5 8 9 7 2			9/28/99	Hupe et al.			
	US 6 0 4 8 8 9 8			4/11/00	Konfino et al.			
	US 6 0 5 4 4 3 0			4/25/00	Konfino et al.			
	US 6 2 1 4 7 9 1			4/10/01	Arnon et al.			
	US 6 3 4 2 4 7 6			1/29/02	Konfino et al.			
FOREIGN PATENT DOCUMENTS								
	Document Number	Date	Country	Class	Subclass	Translation		
						Yes	No	
	WO 0 0 2 0 0 1 0	4/13/00	US					
	WO 0 0 2 7 4 1 7	5/18/00	US					
	WO 0 0 0 5 2 4 9	2/3/00	US					
	WO 0 0 2 0 0 1 0	4/13/00	US					
	WO 0 1 6 0 3 9 2	8/23/01	US					
	WO 0 1 9 3 8 2 8	12/13/01	US					
	WO 0 1 9 7 8 4 6	12/27/01	US					
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
	Webb, et al., "In Vivo and in Vitro Immunological Cross-reactions between Basic Encephalitogen and Synthetic Basic Polypeptides Capable of Suppressing Experimental Allergic Encephalomyelitis", <i>Eur. J. Immunol.</i> , 1973, 3, 279-286							
	Teitelbaum, et al., "Dose-response Studies on Experimental Allergic Encephalomyelitis Suppression by COP-1", <i>Israel J. Med. Sci.</i> , 1974, 10(9), 1172-1173							
	Teitelbaum, et al., "Suppression of Experimental Allergic Encephalomyelitis in Rhesus Monkeys by a Synthetic Basic Copolymer", <i>Clin. Immunol. Immunopath.</i> , 1974, 3, 256-262							
	Webb, et al., "Suppression of Experimental Allergic Encephalomyelitis in Rhesus Monkeys by a Synthetic Basic Copolymer", <i>Isr. J. Med. Sci.</i> , 1975, 11, 1388 (Abstract)							
EXAMINER		DATE CONSIDERED						
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office						Atty. Docket No. 60623-A	Serial No. 09/788,131	
		INFORMATION DISCLOSURE CITATION O I P E (Use several sheets if necessary)						Applicants Adrian Gilbert et al.		
								Filing Date February 16, 2001	Group Art Unit 1614	
<b>JUL 08 2002</b> <i>SCI</i> <b>U.S. PATENT DOCUMENTS</b>										
Examiner Initial		Document Number			Date	Name		Class	Subclass	Filing Date if Appropriate
		US	09	3 5 9 0 9 9	7/22/99	Strominger et al.				
		US	09	4 0 5 7 4 3	9/24/99	Gad et al.				
		US	09	7 6 8 8 7 2	1/23/01	Aharoni et al.				
		US	09	8 1 6 9 8 9	3/23/01	Gad et al.				
		US	09	8 7 5 4 2 9	6/5/01	Yong and Chabot.				
		US	09	8 8 5 2 2 7	6/20/01	Rodriguez and Ure.				
<b>FOREIGN PATENT DOCUMENTS</b>										
		Document Number			Date	Country	Class	Subclass	Translation	
		EP	0 3 8 3 6 2 0		8/22/90	Europe			Yes	No
		EP	0 3 5 9 7 8 3		11/29/95	Europe				
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>										
		Webb, et al., "Molecular Requirements Involved in Suppression of EAE by Synthetic Basic Copolymers of Amino Acids", <u>Immunochem.</u> , 1976, <u>13</u> , 333-337								
		Abramsky, et al., "Effect of a Synthetic Polypeptide (COP-1) on Patients with Multiple Sclerosis and with Acute Disseminated Encephalomyelitis", <u>J. Neurol. Sci.</u> , 1977, <u>31</u> , 433-438								
		Teitelbaum, et al., "Suppression of Experimental Allergic Encephalomyelitis in Baboons by Cop 1", <u>Israel J. Med. Sci.</u> , 1977, <u>13</u> , 1038 (Abstract)								
		Arnon, et al., "Suppression of EAE in Baboons by a Synthetic Polymer of Amino Acids", <u>Neurol.</u> , 1978, <u>28</u> , 336 (Abstract)								
		Sela, et al., "Experimental Allergic Encephalomyelitis" in <u>Menarini Series on Immunopathology</u> , vol. 1, <u>First Symposium of Organ Specific Autoimmunity</u> , Cremona, Italy, June, 1977, (Miescher P.A. ed., Schwabe Co., Basel, 1978), 9-21								
		Alvord, et al., "Myelin Basic Protein Treatment of Experimental Allergic Encephalomyelitis in Monkeys", <u>Ann. Neurol.</u> , 1979, <u>6</u> , 469-473								
		Keith, et al., "The Effect of COP 1, a Synthetic Polypeptide, on Chronic Relapsing Experimental Allergic Encephalomyelitis in Guinea Pigs" <u>J. Neurol. Sci.</u> , 1979, <u>42</u> , 267-274								
		Lando, et al., "Effect of Cyclophosphamide on Suppressor Cell Activity in Mice Unresponsive to EAE", <u>J. Immunol.</u> , 1979, <u>123</u> , 2156-2160 (Abstract)								
EXAMINER			DATE CONSIDERED							
<b>*EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.										

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 60623-A	Serial No. 09/788,131
O I P E INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		Applicants Adrian Gilbert et al.	
JUL 08 2002 U. S. PATENT & TRADEMARK OFFICE		Filing date February 16, 2001	Group Art Unit 1614

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Lando, et al., "Experimental Allergic Encephalomyelitis in Mice - Suppression and Prevention with COP-1", <u>Israel J. Med. Sci.</u> , 1979, <u>15</u> , 868-869 (Abstract)
	Teitelbaum, et al., "Blocking of Sensitization to Encephalitogenic Basic Protein in Vitro by Synthetic Basic Copolymer (COP 1)" in <u>Cell Biology and Immunology of Leukocyte Function</u> (Academic Press, New York, 1979) 681-685
	Teitelbaum, "Suppression of Experimental Allergic Encephalomyelitis with a Synthetic Copolymer - Relevance to Multiple Sclerosis", in <u>Humoral Immunity in Neurological Diseases</u> (Karcher D., Lowenthal A. & Strosberg A.D., eds., Plenum Publishing Corp., 1979) 609-613
	Arnon, et al., "Desensitization of Experimental Allergic Encephalomyelitis with Synthetic Peptide Analogues" in <u>The Suppression of Experimental Allergic Encephalomyelitis and Multiple Sclerosis</u> (Academic Press, New York, 1980) 105-107
	Arnon, "A Synthetic Copolymer of Amino Acids in a Clinical Trial for MS Therapy" in <u>Progress in Multiple Sclerosis Research</u> (Bauer, Ritter, eds., Springer Verlag New York, 1980) 416-418
	Bornstein, et al., "Treatment of Multiple Sclerosis with a Synthetic Polypeptide: Preliminary Results", <u>Ann. Neurol.</u> , 1980, <u>8</u> , 117 (Abstract)
	Bornstein, et al., "Treatment of Multiple Sclerosis with a Synthetic Polypeptide: Preliminary Results", <u>Trans. Am. Neurol. Assoc.</u> , 1980, <u>105</u> , 348-350
	McDermott, et al., "Antigen-induced Suppression of Experimental Allergic Neuritis in the Guinea Pig", <u>J. Neurol. Sci.</u> , 1980, <u>46</u> , 137-143
	Arnon, "Experimental Allergic Encephalomyelitis - Susceptibility and Suppression", <u>Immunological Rev.</u> , 1981, <u>55</u> , 5-30
	Bornstein, et al., "Multiple Sclerosis: Trial of a Synthetic Polypeptide", <u>Ann. Neurol.</u> , 1982, <u>11</u> , 317-319
	Brosnan, et al., "The Response of Normal Human Lymphocytes to Copolymer 1", <u>J. Neuropath. Exp. Neurol.</u> , 1983, <u>42</u> , 356 (Abstract)
	Lisak, et al., "Effect of Treatment with Copolymer 1 (Cop-1) on the in Vivo and in Vitro Manifestations of Experimental Allergic Encephalomyelitis (EAE)", <u>J. Neurol. Sci.</u> , 1983, <u>62</u> , 281-293
	Bornstein, et al., "Clinical Trials of Copolymer 1 in Multiple Sclerosis", <u>Ann. N.Y. Acad. Sci. (USA)</u> , 1984, 366-372

EXAMINER	DATE CONSIDERED
----------	-----------------

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 60623-A	Serial No. 09/788,131
O I P INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		Applicants Adrian Gilbert et al.		
JUL 08 2002 PATENT & TRADEMARK OFFICE SEARCHED & SERIALIZED		Filing date February 16, 2001	Group Art Unit 1614	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
Bornstein, et al., "Clinical Trials of a Synthetic Polypeptide (Copolymer 1) for the Treatment of Multiple Sclerosis" in Gonsett et al., <u>Immunological and Clinical Aspects of Multiple Sclerosis</u> (MTP Press, The Hague, 1984) 144-150				
Brosnan, et al., "Copolymer 1: Effect on Normal Human Lymphocytes", <u>Ann. N.Y. Acad. Sci. (USA)</u> , 1984, <u>436</u> , 498-499				
Bornstein, et al., "Multiple Sclerosis: Clinical Trials of a Synthetic Polypeptide, Copolymer 1", <u>Neurol.</u> , 1985, <u>35</u> (Suppl. 1), 103 (Abstract)				
Brosnan, et al., "Immunogenic Potentials of Copolymer 1 in Normal Human Lymphocytes", <u>Neurol.</u> , 1985, <u>35</u> , 1754-1759				
Burns, et al., "Human Cellular Immune Response in Vitro to Copolymer 1 and Myelin Basic Protein (MBP)", <u>Neurol.</u> , 1985, <u>35</u> (Suppl. 1), 170 (Abstract)				
Teitelbaum, et al., "Monoclonal Antibodies to Myelin Basic Protein Cross React with Synthetic EAE-suppressive Copolymer, COP 1" in <u>Proc. 7<sup>th</sup> Eur. Immunol. Mtg.</u> , Jerusalem, September 8-13, 1985 (Abstract)				
Thompson, "MCQ Tutor: Medical Immunology Multiple Choice Questions", <u>Immunol. Today</u> , 1985, <u>6</u> (4), 141				
Burns, et al., "Human Cellular Immune Response to Copolymer 1 and Myelin Basic Protein", <u>Neurol.</u> , 1986, <u>36</u> , 92-94				
Bornstein, "Cop 1 May be Beneficial for Patients with Exacerbating-remitting Form of Multiple Sclerosis", <u>Adv. Ther. (USA)</u> , 1987, <u>4</u> , 206 (Abstract)				
Bornstein, et al., "A Pilot Trial of Cop 1 in Exacerbating-remitting Multiple Sclerosis", <u>New Eng. J. Med.</u> , 1987, <u>317</u> (7), 408-414				
Rolak, "Copolymer-I Therapy for Multiple Sclerosis", <u>Clin. Neuropharmacology</u> , 1987, <u>10</u> (5), 389-396				
Winer, "COP 1 Therapy for Multiple Sclerosis", <u>New Eng. J. Med.</u> , 1987, <u>317</u> (7), 442-444				
Arnon, et al., "Suppression of Demyelinating Diseases by Synthetic Copolymers", in <u>A Multidisciplinary Approach to Myelin Disease</u> (G. Serlupi Crescenzi, ed., Plenum Publishing Corp., 1988) 243-250				
Baumhefner, et al., "Copolymer 1 as Therapy for Multiple Sclerosis: The Cons", <u>Neurol.</u> , 1988, <u>38</u> (Suppl. 2), 69-71				
Bornstein, et al., "Clinical Experience with COP-1 in Multiple Sclerosis", <u>Neurol.</u> , 1988, <u>38</u> (Suppl. 2), 66-69				
EXAMINER	DATE CONSIDERED			
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>				

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 60623-A	Serial No. 09/788,131
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)				Applicants Adrian Gilbert et al.	
				Filing date February 16, 2001	Group Art Unit 1614
O I P E OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
JUL 08 2002					
<p>Teitelbaum, et al., "Specific Inhibition of the T-cell Response to Myelin Basic Protein by the Synthetic Copolymer Cop 1", <u>Proc. Natl. Acad. Sci. USA</u>, 1988, <u>85</u>, 9724-9728</p> <p>Arnon, et al., "Suppression of Experimental Allergic Encephalomyelitis by Cop-1 - Relevance to Multiple Sclerosis", <u>Israel J. Med. Sci.</u>, 1989, <u>25</u>, 686-689</p> <p>Bornstein, et al., "Pilot Trial of COP-1 in Chronic Progressive Multiple Sclerosis: Preliminary Report", from <u>The International Multiple Sclerosis Conference: An Update on Multiple Sclerosis</u>, Roma (Italy), September 15-17, 1988, in <u>Elsevier Science Publisher</u>, 1989, 225-232</p> <p>Teitelbaum, et al., "Clinical Trial of Copolymer 1 in Multiple Sclerosis" <u>J. Israel Med. Assoc.</u>, 1989, <u>CXVI</u>(9), 453-456</p> <p>Bornstein, et al., "Clinical Trials of Cop 1 in Multiple Sclerosis" in <u>Handbook of Multiple Sclerosis</u> (S.D. Cook Marcel Rekker, ed., 1990) 469-480</p> <p>Carter, et al., "Newer Drug Therapies for Multiple Sclerosis", <u>Drug Therapy</u>, 1990, 31-32, 37-39, 42-43</p> <p>Grgacic, et al., "Cell-mediated Immune Response to Copolymer 1 in Multiple Sclerosis Measured by the Macrophage Procoagulant Activity Assay", <u>Int. Immunol.</u>, 1990, <u>2</u>(8), 713-718</p> <p>Kay, et al., "The Mechanism of Action of FK 506", <u>Transplantation Proceedings</u>, 1990, <u>22</u>(1, Suppl. 1), 96-99</p> <p>Lee, et al., "Peptide and Protein Drug Delivery" in <u>Advances in Parenteral Sciences</u> (Vincent H.L. Lee, ed., Marcel Dekker, Inc., 1990) 691-695</p> <p>Myers, et al., "The Peculiar Difficulties of Therapeutic Trials for Multiple Sclerosis", <u>Neurologic Clinics</u>, 1990, <u>8</u>(1), 119-141</p> <p>Sela, et al., "Suppressive Activity of COP-1 in EAE and its Relevance to Multiple Sclerosis", <u>Bull. Inst. Pasteur</u>, 1990, <u>88</u>, 303-314</p> <p>Starzl, <u>Transplantation Proceedings</u>, 1990, <u>22</u> (1, Suppl. 1), 5</p> <p>Wender, "Copolymer 1 (COP-1) in the Treatment of Multiple Sclerosis (letter)" <u>Neur. Neurochir. Pol.</u>, 1990, <u>24</u>, 113</p> <p>Bornstein, et al., "A Placebo-controlled, Double-blind, Randomized Two-center, Pilot Trial of Cop 1 in Chronic Progressive Multiple Sclerosis", <u>Neurol.</u>, 1991, <u>41</u>, 533-539</p> <p>Burns, et al., "Failure of Copolymer 1 to Inhibit the Human T-cell Response to Myelin Basic Protein", <u>Neurol.</u>, 1991, <u>41</u>, 1317-1319.</p>					
EXAMINER		DATE CONSIDERED			
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>					

**\*EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
60623-ASerial No.  
09/788,131INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)

Applicants

Adrian Gilbert et al.

Filing date

February 16, 2001

Group Art Unit  
1614

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

JUL 08 2002

*O I P E*

Clinical Trial Protocol No. 9001, Teva Pharmaceutical Industries, Ltd., first patient enrolled October 23, 1991

Ferrara, et al., "Graft-Versus-Host Disease", New Eng. J. Med., 1991, 324, 667-674

Meiner, "COP-1 Multicenter Clinical Trial in Exacerbating-remitting Multiple-Sclerosis: One Year Follow-up", J. Neurol., 1991(Suppl. 1) (Abstract)

Rothbard, et al., "Interactions Between Immunogenic Peptides and MHC Proteins", Ann. Rev. Immunol., 1991, 9, 527-565

Salvetti, et al., "Myelin Basic Protein T Cell Epitopes in Patients with Multiple Sclerosis", Department of Neurological Sciences, University of Rome, La Sapienza 1991, 72 (Abstract)

Teitelbaum, et al., "Cross-reactions and Specificities of Monoclonal Antibodies Against Myelin Basic Protein and Against the Synthetic Copolymer 1", Proc. Natl. Acad. Sci. (USA), 1991, 88, 9528-9532

Van den Bogaerde, et al., "Induction of Long-Term Survival of Hamster Heart Xenografts in Rats", Transplantation, 1991, 52, 15-20

Bornstein, et al., "Treatment of Multiple Sclerosis with Copolymer 1" in Treatment of Multiple Sclerosis: Trial Design, Results and Future Perspectives (Rudick R.A. & Goodkin D.E., eds., Springer Verlag, London, 1992) 173-198

Johnson, "Clinical Studies in Copolymer 1 Therapy for Exacerbating-remitting Multiple Sclerosis", in Congress for Advances in the Understanding and Treatment of Multiple Sclerosis, Boston (USA), Oct. 28-29, 1992

Milo, et al., "Inhibition of Myelin Basic Protein-specific Human T-cell Lines by COP-1", Israel J. Med. Sci., 1992, 28, 486 (Abstract)

Racke, et al., "Copolymer-1-induced Inhibition of Antigen-specific T Cell Activation: Interference with Antigen Presentation", J. Neuroimmunol., 1992, 37, 75-84

Teitelbaum, et al., "Synthetic Copolymer 1 Inhibits Human T-cell Lines Specific for Myelin Basic Protein", Proc. Natl. Acad. Sci. (USA), 1992, 89, 137-141

Weinshenker et al., "Natural History and Treatment of Multiple Sclerosis", Current Opinion in Neurol. and Neurosurgery, 1992, 5, 203-211

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
60623-ASerial N :  
09/788,131INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)Applicants  
Adrian Gilbert et al.Filing date  
February 16, 2001Group Art Unit  
1614

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

JUL 08 2002

SEARCHED	INDEXED	MAILED	Aharoni, et al., "T Suppressor Hybridomas and Interleukin-2-Dependent Lines Induced by Copolymer 1 or by Spinal Cord Homogenate Down-Regulate Experimental Allergic Encephalomyelitis", <u>Eur. J. Immunol.</u> , 1993, <u>23</u> , 17-25
			Arnon, et al., "Immunomodulation of Experimental Allergic Encephalomyelitis", <u>Israel J. Med. Sci.</u> , 1993, <u>29</u> , 175-181
			Arnon, et al., "On the Existence of Suppressor Cells", <u>Int. Arch. Allergy Immunol.</u> , 1993, <u>100</u> , 2-7
			Clinical Trial Protocol No. 9002, Lemmon Co. and Teva Pharmaceutical Industries, Ltd., first patient enrolled June 17, 1993
			Francis, "The Current Therapy of Multiple Sclerosis", <u>J. Clin. Pharmacy and Therapeutics</u> , 1993, <u>18</u> , 77-84
			Keleman, et al., "Graft-versus-Host Disease in Bone Marrow Transplantation: Experimental, Laboratory, and Clinical Contributions of the Last Few Years", <u>Int. Arch. Allergy Immunol.</u> , 1993, <u>102</u> , 309-320
			Gurevich, "Study of the MHC-competition Between BP and Cop 1 Using Human Cytotoxic T-cell Clones", <u>Israel J. Med. Sci.</u> , 1993 (Abstract)
			Meiner, et al., "The Israeli COP-1 Multicenter Clinical Trial in Exacerbating-remitting Multiple Sclerosis - Two-year Follow-up", in <u>9th Congress of the European Committee for Treatment and Research in Multiple Sclerosis</u> , Florence (Italy), October-November, 1993, 48 (Abstract)
			Milo, et al., "Copolymer-1 (COP-1) Regulates Class II MHC Expression and Cytokine Synthesis in the THP-1 Monocyte-Macrophage Cell Line" in <u>The IBC Conference on Multiple Sclerosis</u> , San Diego (USA), December 10, 1993 (Abstract)
			Sela, "Polymeric Drugs as Immunomodulatory Vaccines Against Multiple Sclerosis", <u>Makromol. Chem. Macromol. Symp.</u> , 1993, <u>70/71</u> , 147-155
			Arnon, et al., "Immunospecific Drug Design - Prospects for Treatment of Autoimmune Disease", <u>Therapeutic Immunol.</u> , 1994, <u>1</u> , 65-70
			Bansil, et al., "Multiple Sclerosis: Pathogenesis and Treatment", <u>Seminars in Neurol.</u> , June 1994, <u>14</u> (2), 146-153
			The COP-1 Multicenter Clinical and Research Group Study, "COP-1 Multicenter Trial in Relapsing Remitting Multiple Sclerosis: 3 Year Follow Up", <u>Abstracts of Symposia and Free Communication</u> , Barcelona (Spain), June 25-29, 1994, <u>241</u> (Suppl. 1), 6
			Cotton, "Options for Multiple Sclerosis Therapy", <u>J.A.M.A. Medical News &amp; Perspectives</u> , 1994, <u>272</u> (18), 1393

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 60623-A	Serial No. 09/788,131
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)				Applicants Adrian Gilbert et al.	
				Filing date February 16, 2001	Group Art Unit 1614
<p style="text-align: center;"><i>JUL 08 2002</i> OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</p> <p><i>O I P E K 100 P R E M I U M T R A D E M A R K O F F I C E</i></p>					
<p>Dorfling, et al., "Prospects for Xenografting", <u>Curr. Opinions Immunol.</u>, 1994, 6, 765-769</p>					
<p>Fridkis-Hareli, et al., "Copolymer 1 Displaces MBP, PLP and MOG, but Can Not be Displaced by these Antigens from the MHC Class II Binding Site", <u>Department of Chemical Immunology, The Weizmann Institute of Science</u>, 1994</p>					
<p>Fridkis-Hareli, et al., "Direct Binding of Myelin Basic Protein and Synthetic Copolymer 1 to Class II Major Histocompatibility Complex Molecules on Living Antigen-Presenting Cells - Specificity and Promiscuity", <u>Proc. Natl. Acad. Sci. USA</u>, 1994, 91, 4872-4876</p>					
<p>Fridkis-Hareli, et al., "Specific and Promiscuous Binding of Synthetic Copolymer 1 to Class II Major Histocompatibility Complex Molecules on Living Antigen Presenting Cells", <u>Israeli Biochem. Soc.</u>, 1994, 21-22 (Abstract)</p>					
<p>Fridkis-Hareli, et al., "Synthetic Copolymer 1 Inhibits the Binding of MBP, PLP and MOG Peptides to Class II Major Histocompatibility Complex Molecules on Antigen Presenting Cells" in <u>Neurochem Mtg.</u>, August 14-19, 1994</p>					
<p>Fridkis-Hareli, et al., "Synthetic Copolymer 1 Inhibits the Binding of MBP, PLP and MOG Peptides to Class II Major Histocompatibility Complex Molecules on Antigen- Presenting Cells", <u>J. Neurochem.</u>, 1994, 63(Suppl. I), 561</p>					
<p>Fridkis-Hareli, et al., "Synthetic Copolymer 1 and Myelin Basic Protein Do Not Undergo Processing Prior to the Binding to Class II Major Histocompatibility Complex Molecules on Antigen Presenting Cells", <u>Israeli Immunol. Soc.</u>, May 3-4, 1994 (Abstract)</p>					
<p>Fridkis-Hareli, et al., "Synthetic Copolymer 1 and Myelin Basic Protein do not Require Processing Prior to Binding to Class II Major Histocompatibility Complex Molecules on Living Antigen Presenting Cells", <u>Department of Chemical Immunology, The Weizmann Institute of Science</u>, Rehovot, Israel, 1994,</p>					
<p>Fridkis-Hareli, et al., "Synthetic Copolymer 1 and Myelin Basic Protein Do Not Require Processing Prior to Binding to Class II Major Histocompatibility Complex Molecules on Living Antigen-Presenting Cells", <u>Cell. Immunol.</u>, 1995, 163, 229-236</p>					
<p>Jacobs et al., "Advances in Specific Therapy for Multiple Sclerosis", <u>Neurol.</u>, 1994, 7, 250-254</p>					
EXAMINER	DATE CONSIDERED				
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>					

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
60623-ASerial No.  
09/788,131INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)

Applicants

Adrian Gilbert et al.

Filing date

February 16, 2001

Group Art Unit  
1614

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

O I P E JUL 08 2002 P A T E N T & T R A D E M A R K S E R V I C E	Johnson, "Experimental Therapy of Relapsing-Remitting Multiple Sclerosis with Copolymer-1", <u>Ann. Neurol.</u> , 1994, <u>36</u> (Suppl.), 115-117
	Kott, et al., "COP-1 Increases Suppressor Cells Number in Multiple Sclerosis", <u>Israel Neurological Assoc.</u> , December 19-20, 1994, Herzliya (Israel), 17
	Mengle-Gaw, "The Major Histocompatibility Complex (MHC)", in <u>Encycl. Molecular Bio.</u> (Oxford Blackwell Science Ltd, 1994) 602-606
	Milo, et al., "Additive Effects of COP-1 and IFN-Beta on Immune Responses to Myelin Basic Protein", <u>Neurol.</u> , 1994, <u>44</u> (Suppl. 2), A212
	Milo, et al., "Additive Effect of Copolymer-1 and Interferon-β on the Immune Response to Myelin Basic Protein", <u>Assaf Harofeh Medical Center, Sackler School of Medicine, Tel-Aviv University of Maryland School of Medicine</u> , 1994, 22
	Milo, et al., "Copolymer-1 and Interferon-β Additively Suppress the Immune Response to Myelin Basic Protein by Inhibiting Antigen Presentation", <u>J. Neuroimmunol.</u> , 1994, <u>54</u> , 183 (Abstract)
	Nightingale, et al., "Access to Investigational Drugs for Treatment Purposes", <u>Am. Family Physician</u> , 1994, <u>50</u> (4), 845-847
	Schlegel, et al., "Prevention of Graft-Versus-Host Disease by Peptides Binding to Class II Major Histocompatibility Complex Molecules", <u>Blood</u> , 1994, <u>84</u> (8), 2802-2810
	Stark, "Expanded Clinical Trials of Treatments for Multiple Sclerosis (MS): Copolymer 1 (COP-1) Treatment Investigational New Drug (IND) Program", <u>Ann. Neurol.</u> , 1994, <u>36</u> , 114-115
	Teitelbaum, et al., "Immunological Parameters in a Multicenter Clinical Trial of COP1 in Multiple Sclerosis (MS): A 2-year Follow-up", <u>Neurol.</u> , 1994, <u>44</u> (Suppl. 2), A358
	Tisch et al., "Antigen-specific immunotherapy: Is it a Real Possibility to Combat T-Cell-Mediated autoimmunity?" <u>Proc. Natl. Acad. Sci. U.S.A.</u> , 1994, <u>91</u> , 437-438
	Milo, et al., "Additive Effects of Copolymer-1 and Interferon β-1b on the Immune Response to Myelin Basic Protein", <u>J. Neuroimmunol.</u> , 1995, <u>61</u> , 185-193
	O'Connor, et al., "Powders" in <u>The Science and Practice of Pharmacy</u> , Remington, 1995, <u>2</u> , 1598-1614
	Porter, "Coating of Pharmaceutical Dosage Forms," in <u>The Science and Practice of Pharmacy</u> , Remington, 1995, <u>2</u> , 1650-1659

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
60623-ASerial No.  
09/788,131INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)Applicants  
Adrian Gilbert et al.Filing date  
February 16, 2001Group Art Unit  
1614

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

REILLY, Jr., W.J., "Pharmaceutical Necessities" in The Science and Practice of Pharmacy, Remington, 1995, 2, 1380-1416

Schlegel, et al., "Inhibition of Allore cognition and Prevention of Graft-vs-host Disease (GVHD) by GLAT, a Synthetic Polymer with Promiscuous Binding to Murine and Human MHC Class II Molecules", in Am. Soc. Hematology, 37<sup>th</sup> Annual Meeting, Seattle, WA (USA), December 1-5, 1995, 224a (Abstract)

Ben-Nun, et al., "The Autoimmune Reactivity to Myelin Oligodendrocyte Glycoprotein (MOG) in Multiple Sclerosis is Potentially Pathogenic: Effect of Copolymer 1 on MOG-induced Disease", J. Neurol., 1996, 243 (Suppl. 1), S14-S22

Johnson, Management of Relapsing/Remitting Multiple Sclerosis with Copolymer 1 (Copaxone)", Chemical Abstracts, 1996, 125, 291993b

Sykes, "Immunobiology of Transplantation", Faseb J., 1996, 10, 721-730

Teitelbaum, et al., "Copolymer 1 Inhibits Chronic Relapsing Experimental Allergic Encephalomyelitis Induced by Proteolipid Protein (PLP) Peptides in Mice and Interferes with PLP-specific T Cell Responses", J. Neuroimmunol., 1996, 64, 209-217

Aharoni, et al., "Studies on the Mechanism and Specificity of the Effect of the Synthetic Random Copolymer GLAT on Graft-versus-Host Disease", Immunol. Letters, 1997, 58, 79-87

Puri et al., "Modulation of the Immune Response in Multiple Sclerosis", J. Immunol., 1997, 158, 2471-2476

Tarcic et al., "Copolymer 1 (Copaxone) from an Idea to a Drug for Treatment of Multiple Sclerosis" Database HCAPLUS on STN, Israel: AN 1997:333270. Kim, Handasa Kim, 1997, 281(14), 16-18 (Abstract)

Teitelbaum, et al., "Copolymer 1 from the Laboratory to FDA", Israel J. Med. Sci., 1997, 33, 280-284

Fridkis-Hareli, et al., "Promiscuous Binding of Synthetic Copolymer 1 to Purified HLA-DR Molecules", J. Immunol., 1998, 160, 4386-4397

Fridkis-Hareli, et al., "Synthetic Amino Acid Copolymers that Bind to HLA-DR Proteins and Inhibit Type II Collagen-reactive T Cell Clones", Proc. Natl. Acad. Sci., October 1998, 95, 12528-12531

Cazzato, et al., "Treatment of Multiple Sclerosis. The Present and the Future. Study Group on Diagnosis and Therapy of Multiple Sclerosis", Database Medline on STN, Instituto do Clinica Neurologica, Universit`a, Trieste, Italy: Medline AN: 2000060325, Recent Progressi in Medicina. October 1999, 90(10), 538-544 (Abstract)

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
60623-ASerial No.  
09/788,131O I P E INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)Applicants  
Adrian Gilbert et al.Filing date  
February 16, 2001Group Art Unit  
1614

JUL 08 2002

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Repsutlu et al., "Evaluation of Chitosan Used as an Excipient in Tablet Formulations", Database HCPLUS on STN, Department of Pharmaceutical Technology, Gulhane Military Medical Academy, Ankara, 06018, Turkey, HCPLUS AN: 1999: 590411, Acta. Pol. Pharm. 1999, 56(3), 227-235 (Abstract)

Prat, et al., "Lymphocyte Migration and Multiple Sclerosis: Relation with Disease Course and Therapy," Ann. Neurol., 46, 253-256 (1999)

Fridkis-Hareli et al., "Synthetic Peptides that Inhibit Binding of the Collagen Type II 261-273 Epitope to Rheumatoid Arthritis-Associated HLA-DR1 and DR4 Molecules and Collagen-Specific T-cell Responses", Database HCPLUS on STN, Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark, HCPLUS AN: 2000:455053, Human Immunology, 2000, 61(7), 640-650 (Abstract)

Durelli, "Immunotherapy of Multiple Sclerosis", Instituto di Clinica delle Malattie del Sistema Nervoso Universita di Torino, 467-475

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.